17 March 2020 | News
The candidate was selected from APRINOIA's proprietary antibody platform
Image credit- shuttershock.com
South Korea based Samsung Biologics has entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau monoclonal antibody candidate to treat primary and secondary tauopathies, including Progressive Supranuclear Palsy and Alzheimer's disease, which are all currently incurable.
The candidate was selected from APRINOIA's proprietary antibody platform to target specific pathological tau aggregates with novel conformation-dependent epitopes, aiming to slow down disease progression. APRINOIA Therapeutics, headquartered in Taipei, is a clinical-stage biotechnology company developing novel therapeutics and PET imaging diagnostics for neurodegenerative diseases.
Samsung Biologics offers fully integrated development and manufacturing services at the largest single plant, enabling faster and better processes well suited to clients of all sizes at every stage of the biopharmaceutical lifecycle. Through this partnership with APRINOIA, which covers the full scope of the candidate product's development phase from cell line development, process development, cGMP manufacturing to IND filing support, Samsung Biologics has reconfirmed its position as a global leading CMO, CDO, and CRO partner.